THE CLINICAL AND ECONOMIC VALUE OF A SUSTAINED RESPONSE IN THE TREATMENT OF MODERATE-TO-SEVERE PSORIASIS IN SPAIN: THE PSOVALUE PROJECT

Álvaro Hidalgo-Vega1,2, Néboa Zozaya3, María Merino4, Fernando Abdalla5, Paulina Maravilla-Herrera4, Santiago Alfonso Zamora5, Jesús Balea Filgueiras6, José Manuel Carrascosa Carrillo7, Olga Delgado Sánchez8, Francisco Dolz Sinisterra9, Antonio García-Ruiz10, Pedro Herranz Pinto11, Antonio Manfredi5, José Martínez Olmos12, Paloma Morales de los Ríos Luna13, Lluis Puig14, Sandra Ros15

OBJECTIVES

The PSOVALUE project pursued a triple objective related to the management of patients with moderate-to-severe plaque psoriasis in Spain: 1) to identify and quantify unmet needs; 2) to determine, through a multi-criteria decision analysis (MCDA), the value contribution of a new biologic drug; 3) to analyse the social value of achieving a sustained response to treatment.

METHODS

A mixed-methods approach was used: scientific literature review, a focus group with patients, and an advisory multidisciplinary committee composed by twelve experts. 1) A structured questionnaire was designed to elicit unmet needs. 2) The estimated added value of bimekizumab, compared to six alternatives, was obtained by combining weights and scores assigned by the committee based on a matrix of evidence created from a literature review. 3) An economic 1-year time horizon model was applied to estimate the social value of having a Psoriasis Area Severity Index (PASI) 90 or PASI 100 response in comparison with a PASI 75 response.

RESULTS

1) A total of 65 unmet needs were identified and categorized into four areas: clinical, patient related, decision-making process, and social. The most relevant unmet needs were to incorporate outcomes that are important to patients and to have treatments that achieve total clearance with a quick onset of action and long-term persistence (Figure 1). 2) Bimekizumab was assessed as an intervention with a positive value contribution in comparison to any of the alternatives, as it combines a higher level of clearance, rapidity, and persistence with a similar safety/tolerability profile (Figure 2). 3) Moving from a partial response (PASI 75) to a complete response (PASI 100) would represent an added social value of € 4,786 per patient, mainly attributed to work productivity gains (Figure 3).

CONCLUSION

A sustained response in the treatment of moderate-to-severe psoriasis would address relevant unmet needs and generate a substantial social value. Bimekizumab would add value to current treatment options.

AFFILIATIONS

1Weber Foundation, Madrid, Spain; 2Department of Economic Analysis and Finances, University of Castilla-La Mancha. Toledo, Spain; 3Department of Health Economics, Weber, Madrid, Spain; 4Department of Health Outcomes Research, Weber, Madrid, Spain; 5Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain; 6Department of Pharmacy, Ferrol University Hospital Complex, La Coruña, Spain; 7Department of Dermatology, Germans Trias i Pujol University Hospital, Badalona, Spain; 8Department of Management, Spanish Society of Hospital Pharmacy (SEFH), Department of Pharmacy, Son Espases University Hospital, Illes Balears, Spain; 9Department of Management, Psoriasis and Psoriatic Arthritis Patient and Family Association (Acción Psoriasis), Barcelona, Spain; 10Health Economics and Rational Use of Medicines. Department of Pharmacology and Clinical Therapeutics, Biomedical Research Institute of Malaga (IBIMA). University of Malaga, Malaga, Spain; 11Department of Dermatology, La Paz University Hospital, Madrid, Spain; 12Andalusian Public Health School (EASP), Granada, Spain; 13Department of Nursing, Gregorio Marañón University Hospital, Madrid, Spain; 14Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; 15Psychologist, Department of Dermatology, Rheumatology and Cardiac Transplantation, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.